1. Home
  2. NUVB vs VMEO Comparison

NUVB vs VMEO Comparison

Compare NUVB & VMEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • VMEO
  • Stock Information
  • Founded
  • NUVB 2018
  • VMEO 2004
  • Country
  • NUVB United States
  • VMEO United States
  • Employees
  • NUVB N/A
  • VMEO N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • VMEO Computer Software: Prepackaged Software
  • Sector
  • NUVB Health Care
  • VMEO Technology
  • Exchange
  • NUVB Nasdaq
  • VMEO Nasdaq
  • Market Cap
  • NUVB 1.1B
  • VMEO 652.9M
  • IPO Year
  • NUVB N/A
  • VMEO N/A
  • Fundamental
  • Price
  • NUVB $5.00
  • VMEO $7.80
  • Analyst Decision
  • NUVB Strong Buy
  • VMEO Hold
  • Analyst Count
  • NUVB 7
  • VMEO 4
  • Target Price
  • NUVB $8.86
  • VMEO $6.81
  • AVG Volume (30 Days)
  • NUVB 9.3M
  • VMEO 1.5M
  • Earning Date
  • NUVB 11-03-2025
  • VMEO 10-28-2025
  • Dividend Yield
  • NUVB N/A
  • VMEO N/A
  • EPS Growth
  • NUVB N/A
  • VMEO N/A
  • EPS
  • NUVB N/A
  • VMEO 0.00
  • Revenue
  • NUVB $26,748,000.00
  • VMEO $416,596,000.00
  • Revenue This Year
  • NUVB $283.17
  • VMEO $2.98
  • Revenue Next Year
  • NUVB $340.98
  • VMEO $4.96
  • P/E Ratio
  • NUVB N/A
  • VMEO $2,369.01
  • Revenue Growth
  • NUVB 1137.19
  • VMEO N/A
  • 52 Week Low
  • NUVB $1.54
  • VMEO $3.64
  • 52 Week High
  • NUVB $5.55
  • VMEO $7.90
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 65.03
  • VMEO 78.77
  • Support Level
  • NUVB $3.92
  • VMEO $7.76
  • Resistance Level
  • NUVB $5.38
  • VMEO $7.82
  • Average True Range (ATR)
  • NUVB 0.43
  • VMEO 0.03
  • MACD
  • NUVB 0.01
  • VMEO -0.07
  • Stochastic Oscillator
  • NUVB 75.24
  • VMEO 72.22

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About VMEO Vimeo Inc.

Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.

Share on Social Networks: